Anthropic, 신약 개발 진출 — AI가 빅파마의 12년 실패율을 고칠 수 있을까?
anthropic이 자사 ai 훈련을 위해 소외질환 대상 사내 신약 개발 프로그램을 시작했으며, 고위험 바이오 응용 분야로의 확장 의지를 시사한다.
anthropic will conduct preclinical research for neglected diseases, citing its nonprofit mission and the need for complex training data to improve its ai models. the announcement accompanied the launch of 'claude science', a tool where a ucsf researcher reportedly used claude to identify a year-old viral contamination in minutes. this strategy aligns with broader industry efforts, such as google's isomorphic labs, to cut drug development timelines from 12 to 8 years.